{"organizations": [], "uuid": "462db2489b78c2916dbd7707fbc5a1bd46c08a3d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mei-pharma-says-interim-data-revie/brief-mei-pharma-says-interim-data-review-supports-continuation-of-me-344-clinical-study-idUSFWN1Q30ZD", "country": "US", "domain_rank": 408, "title": "MEI Pharma Says Interim Data Review Supports Continuation Of ME-344 Clinical Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.602, "site_type": "news", "published": "2018-02-13T21:13:00.000+02:00", "replies_count": 0, "uuid": "462db2489b78c2916dbd7707fbc5a1bd46c08a3d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mei-pharma-says-interim-data-revie/brief-mei-pharma-says-interim-data-review-supports-continuation-of-me-344-clinical-study-idUSFWN1Q30ZD", "ord_in_thread": 0, "title": "MEI Pharma Says Interim Data Review Supports Continuation Of ME-344 Clinical Study", "locations": [], "entities": {"persons": [{"name": "bevacizumab", "sentiment": "none"}], "locations": [], "organizations": [{"name": "mei pharma says interim data review", "sentiment": "negative"}, {"name": "reuters) - mei pharma inc", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - MEI Pharma Inc:\n* MEI PHARMA INTERIM DATA REVIEW SUPPORTS CONTINUATION OF CLINICAL STUDY EVALUATING ME-344 IN PATIENTS WITH BREAST CANCER\n* MEI PHARMA INC - INTERIM STUDY DATA SHOW THAT ME-344 WAS GENERALLY WELL-TOLERATED\n* MEI PHARMA - BASED ON INTERIM STUDY RESULTS, IT WAS DETERMINED THAT COMPLETING ENROLLMENT OF STUDY OF ME-344 IN COMBINATION WITH BEVACIZUMAB IS WARRANTED Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T21:13:00.000+02:00", "crawled": "2018-02-14T12:17:54.005+02:00", "highlightTitle": ""}